Streetbeat News

Revenues

ALUR

Allurion Technologies conducted research showing that nearly 90% of healthcare professionals (HCPs) consider the Allurion Program an ideal first-line treatment for achieving over 10% body weight loss quickly and sustainably. The study involved 172 HCPs and 1663 patients across 64 countries, assessing the impact of growing interest in anti-obesity medications on the awareness and uptake of the Allurion Program.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:16 pm

OSPN

OneSpan Inc. anticipates its fiscal year 2023 revenue to be at the high end of the $228M-$232M range, exceeding the $229.82M estimate. The company also expects to meet or exceed the high end of the $2M-$4M adjusted EBITDA range. Fiscal year 2023 ARR guidance remains at $148M-$152M, with a revenue growth target of low- to mid-single digits for 2024 and an adjusted EBITDA margin target of 20%-23%. OneSpan aims to improve its operating model to reach a 30% level under the 'Rule of 40' by the end of 2024. The company forecasts a year-end cash balance of $41M-$43M, after accounting for stock repurchases, restructuring payments, and other expenditures.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:15 pm

FSK

ML

TW

XYF

Four financial stocks with high RSI values, indicating potential overbought conditions, are X Financial (XYF), Tradeweb Markets Inc. (TW), MoneyLion Inc. (ML), and FS KKR Capital Corp. (FSK). XYF reported strong Q3 results with a 16% stock increase over five days. TW's trading volume grew 43.3% YoY, with a 5% stock gain over five days. ML experienced a 48% stock jump over the past month despite downbeat quarterly sales. FSK's stock rose 4% over five days after pricing a public offering of $400 million notes.

Portfolio Pulse from Avi Kapoor

January 05, 2024 | 1:12 pm

SPRO

Spero Therapeutics has announced that it will soon provide Phase 2a topline proof of concept data for its SPR720 program. Additionally, the company has begun dosing in its PIVOT-PO Phase 3 trial. Spero is also set to receive $95 million in milestone payments as part of a licensing agreement.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:11 pm

NFLX

Netflix Inc. (NASDAQ:NFLX) is exploring ways to monetize its gaming division, considering options such as in-app purchases, charging for premium games, and extending gaming access to ad-tier subscribers. This marks a strategic shift from its previous stance of offering games without monetization to focus on the gaming experience. Despite concerns from some executives and investors about resource allocation, Netflix's gaming has seen growth, with a significant increase in game downloads and plans to enhance its gaming budget for higher quality games.

Portfolio Pulse from Benzinga Neuro

January 05, 2024 | 1:11 pm

IRTC

iRhythm Technologies, Inc. announced the publication of the CAMELOT study results in the American Heart Journal, which demonstrated a higher clinical diagnostic yield and lower odds of restarting with their Zio long-term continuous monitoring (LTCM) product. The findings suggest that Zio LTCM may offer significant benefits in diagnosing heart conditions compared to other methods.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:10 pm

GM

General Motors Co (NYSE:GM) is transitioning its EV lineup after discontinuing the Chevrolet Bolt EV and EUV, which represented over 80% of its 75,000 EVs sold in the U.S. in 2023. The Lake Orion plant, previously producing the Bolt, is being retooled for electric trucks like the Chevrolet Silverado EV and GMC Sierra EV, with production starting in late 2025. GM's short-term EV delivery targets are unclear, but it aims to go all-electric by 2035.

Portfolio Pulse from Anan Ashraf

January 05, 2024 | 1:09 pm

HURC

Hurco Cos (NASDAQ:HURC) reported a 63.64% increase in Q4 EPS to $0.36, up from $0.22 YoY, and a 4.16% increase in sales to $66.11M, up from $63.46M YoY.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:08 pm

PRAX

Praxis Precision Medicines, Inc. has entered into a licensing and collaboration agreement with Tenacia Biotechnology for the development and commercialization of ulixacaltamide in Greater China. Praxis will receive $15 million upfront, with the potential for up to $264 million in milestone payments and tiered royalties on net sales. The collaboration aims to address the unmet need for essential tremor treatments in the region.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:08 pm

INSM

Insmed Incorporated (NASDAQ:INSM) provided a business update at the 42nd Annual J.P. Morgan Healthcare Conference, forecasting 2024 global ARIKAYCE revenues of $340M-$360M, exceeding FY23 guidance with unaudited sales of ~$305.2M. The company expects significant growth and transformative developments in 2024, including topline data from Phase 3 ASPEN study of Brensocatib and Phase 2 study of TPIP. Insmed's early-stage research comprises over 30 pre-clinical programs, with less than 20% of overall spend.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:06 pm